Cipla Limited
CIPLA
Rank in Stocks
#1816
Cipla Limited, along with its associated entities, operates as a global... Cipla Limited, along with its associated entities, operates as a global pharmaceutical enterprise, specializing in the creation and distribution of a wide array of medicinal products. Its extensive portfolio includes both active pharmaceutical ingredients (APIs) and a diverse range of finished formulations, addressing numerous therapeutic areas such as cardiovascular diseases, metabolic disorders, HIV, respiratory conditions, urology, oncology, pediatric health, infectious diseases, critical care, hepatitis, women's health, ophthalmology, and neuropsychiatry. The company maintains a strong focus on respiratory treatments, offering various inhalers, nasal sprays, injectables, and biosimilars. Cipla has also forged significant partnerships, including a licensing arrangement with Merck & Co., Inc. for the manufacturing and commercialization of the investigational oral antiviral drug Molnupiravir, and a separate license agreement with Eli Lilly and Company for baricitinib, indicated for COVID-19. Furthermore, it collaborates with Dr. Reddy's Laboratories Ltd, Sun Pharmaceutical Industries Limited, Emcure Pharmaceuticals Limited, and Torrent Pharmaceuticals Limited for Molnupiravir's clinical trials. Established in 1935, Cipla's corporate headquarters are located in Mumbai, India.
Share Price
$14.61
Market Cap
$11.80B
Change (1 day)
-0.12%
Change (1 year)
-18.47%
Country
IN
Trade Cipla Limited (CIPLA)
Category
Healthcare
Number of shares outstanding for Cipla Limited (CIPLA)
Number of shares outstanding as of June 2026: 807.63M
According to Cipla Limited latest financial reports and stock price the company's current number of shares outstanding is 807.63M. At the end of March 2024 the company had 807.35M shares outstanding. The number of outstanding shares is usually impacted by stock plits and shares buy back.
Shares outstanding history for Cipla Limited (CIPLA) from 2004 to 2026
Shares Outstanding at the end of each year
| Year | Shares Outstanding | Change |
|---|---|---|
| 2026 (TTM) | 807.63M | -0.07% |
| 2025 | 808.17M | 0.10% |
| 2024 | 807.35M | 0.04% |
| 2023 | 807.01M | 0.04% |
| 2022 | 806.67M | 0.04% |
| 2021 | 806.36M | 0.04% |
| 2020 | 806.02M | 0.08% |
| 2019 | 805.36M | 0.07% |
| 2018 | 804.77M | 0.10% |
| 2017 | 803.98M | 0.10% |
| 2016 | 803.14M | 0.03% |
| 2015 | 802.93M | 0.00% |
| 2014 | 802.92M | 0.00% |
| 2013 | 802.92M | 0.00% |
| 2012 | 802.92M | 0.00% |
| 2011 | 802.92M | 1.62% |
| 2010 | 790.14M | 1.65% |
| 2009 | 777.29M | 0.00% |
| 2008 | 777.29M | 0.18% |
| 2007 | 775.93M | 3.50% |
| 2006 | 749.68M | 0.00% |
| 2005 | 749.68M | 0.00% |
| 2004 | 749.65M | 0.00% |
Shares Outstanding for similar companies or competitors
| Company | Shares Outstanding | Difference | Country |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| - | - |
JP
|
|
| - | - |
CH
|
|
| 2.40B | 197.09% |
IN
|
